Genentech Inc.
Joseph Edelman of Prudential Securities upgraded Genentech Inc. to "buy" from "hold" following positive results in the GUSTO trial comparing GNE's Activase with streptokinase. The two essential questions now, he wrote, are whether doctors will accept the trial result, given data from earlier trials showing the two drugs to be equally effective; and whether